A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics of SR419 in Healthy Volunteers
Latest Information Update: 02 Dec 2024
At a glance
- Drugs SR 419 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; First in man
- Sponsors SIMR Biotech
Most Recent Events
- 20 Sep 2020 Results presented in the SIMR Biotech Media Release.
- 11 Dec 2019 Status changed from recruiting to completed.
- 26 Jul 2019 Status changed from not yet recruiting to recruiting, according to a Shanghai SIMR Biotechnology Co media release.